GeoVax Labs, Inc. (OTCQB: GOVX) is a clinical-stage biotechnology company developing human vaccines against infectious diseases using their vaccine platform, and their current development programs are focused on vaccines against Ebola and Marburg viruses, and Human Immunodeficiency Virus (HIV), according to the company’s website (see here: www.GeoVax.com). SNNLive caught up with Robert T. McNally, Ph.D., President and CEO of GeoVax Labs, Inc at the Marcum MicroCap Conference 2015 in New York City, NY.
Dr. McNally begins with a brief overview of the company. We last spoke with Dr. McNally in January 2015 in San Francisco (see here: GeoVax Labs, Inc. – Developing Vaccines to Combat HIV/AIDS and Ebola Virus), and in this interview he provides an update, “We’re going to be a second generation Ebola vaccine, by that I mean, this first generation product, these are vaccines that have been kind of rushed to quell the epidemic, and there’s really been no real conclusion from that. But as a second-generation product, we’re using some of the latest viral constructs to make it. We’re using our HIV viral delivery system for this vaccine, and we’ve started our vaccinations in small animal models.”
Dr. McNally continues a quick explanation about the science behind the Company’s second-generation Ebola vaccine, where the Company will be conducting the trials, how Ebola is spread, and his insights into 2015-2016. He concludes with the difference between vaccines and treatments, and why the Company is focused on vaccine development.
Since speaking with Dr. McNally, the Company has made the following announcements:
For more information about GeoVax Labs, Inc., go to: www.GeoVax.com
© 2017 Stock News Now
Supported by Superior Web Solutions